
    
      In recent years, newer oral P2Y12 receptor blockers (prasugrel or ticagrelor) have been
      strong recommendations for management of patients with ACS undergoing (PCI). These drugs
      provided more profound inhibitory effects than clopidogrel, which could lead to marked
      reduction in ischemic events, with relatively increase in bleeding complication, specific to
      low body weight, especially in women and East Asian patients.
    
  